Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps put ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...

Dexcom has rebounded since my last update, but I maintain a 'Hold' rating due to continued overvaluation and limited upside potential. Growth remains solid, especially in sensors and U.S. expansion, ...

DexCom, Inc. (NASDAQ:DXCM) shareholders should be happy to see the share price up 12% in the last month. But that doesn't help the fact that the three year return is less impressive. In fact, the ...

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus Estimate of 57 cents by 7%. The company reported earnings of 45 cents per ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...

DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...